Search | Clinical Trials Finder

Conditions: Breast Neoplasms
Interventions: Nanoparticle albumin bound paclitaxel followed by FEC; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 5,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 146
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 123 more

Conditions: Metastatic Colorectal Cancer
Interventions: Pembrolizumab, Pemetrexed, Oxaliplatin, Dexamethasone, Folic Acid, Vitamin B-12; Drug · Dietary Supplement
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 15
States / cities: Gainesville, Florida • Decatur, Illinois • Effingham, Illinois + 8 more

Conditions: Breast Neoplasms
Interventions: ZD1839 in combination with docetaxel; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Letrozole, Palbociclib, Goserelin, Oncotype DX Breast Recurrence Score; Drug · Diagnostic Test
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Fountain Valley, California • Laguna Hills, California • Long Beach, California + 5 more

Conditions: Colorectal Neoplasms, Neoplasm Metastasis
Interventions: Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 87
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more

Conditions: Colorectal Neoplasms
Interventions: Bevacizumab, Oxaliplatin, Capecitabine, Irinotecan; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Letrozole, Placebo; Drug · Other
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 3,966 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2025
U.S. locations: 777
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 523 more

Conditions: Breast Cancer
Interventions: Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 35
States / cities: Huntsville, Alabama • San Diego, California • Vallejo, California + 29 more

Conditions: Colon Cancer
Interventions: Gevokizumab, Signatera test; Drug · Diagnostic Test
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Gainesville, Florida • Iowa City, Iowa • New Brunswick, New Jersey + 2 more

Conditions: Stage III (IIIB or IIIC) Colon Cancer
Interventions: Regorafenib, Placebo; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 51
States / cities: Orange, California • Santa Rosa, California • Vallejo, California + 47 more

Conditions: Colorectal Cancer
Interventions: Cetuximab, Neratinib; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Gainesville, Florida • Orlando, Florida • Boise, Idaho + 7 more

Conditions: Breast Cancer
Interventions: Paclitaxel, trastuzumab, pertuzumab; Drug · Biological
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 5
States / cities: Gainesville, Florida • St Louis, Missouri • New York, New York + 2 more

Conditions: Colon Cancer, Rectal Cancer
Interventions: Cetuximab, Irinotecan, IMC-A12 (cixutumumab); Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Vallejo, California • Greenville, North Carolina • Scranton, Pennsylvania

Conditions: Invasive Breast Cancer
Interventions: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, lapatinib; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 103
States / cities: Mobile, Alabama • La Jolla, California • Long Beach, California + 88 more

Conditions: Breast Cancer, Perioperative/Postoperative Complications
Interventions: patient interviewing to obtain menstrual history, blood sampling; Behavioral · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2009
U.S. locations: 52
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more

Conditions: Breast Cancer
Interventions: Neratinib, T-DM1; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 15
States / cities: Weston, Florida • Decatur, Illinois • Effingham, Illinois + 7 more

Conditions: Breast Cancer
Interventions: anastrozole, tamoxifen citrate, Radiation Therapy; Drug · Radiation
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: Female only
Enrollment: 3,104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 724
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 499 more

Conditions: Colorectal Cancer
Interventions: MRD; Device
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,017 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 28
States / cities: Mission Hills, California • Torrance, California • Gainesville, Florida + 25 more

Conditions: Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen Citrate; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 10,273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1160
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 723 more

Conditions: Breast Cancer
Interventions: ctDNA MRD test; Diagnostic Test
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 53
States / cities: Anchorage, Alaska • Palo Alto, California • Torrance, California + 45 more

Conditions: Breast Cancer
Interventions: 3-dimensional conformal accelerated partial breast irradiation, brachytherapy, whole breast irradiation, MammoSite or other single-entry intracavitary device; Radiation
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 4,216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 374
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 295 more

Conditions: Breast Cancer
Interventions: Bevacizumab, Doxorubicin, Cyclophosphamide, Capecitabine, Docetaxel; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Paclitaxel, Trastuzumab, Neratinib, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 30
States / cities: Loma Linda, California • San Diego, California • Denver, Colorado + 25 more

Search by objective public record fields.

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

NSABP Biospecimen Discovery Project

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy

CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer